Levetiracetam in Central Pain in Multiple Sclerosis(MS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Multiple sclerosis is often associated with pain. There is no standard treatment of this type of pain. Levetiracetam is a new anticonvulsant and it is the hypothesis that it could relieve central pain in multiple sclerosis. This is a randomised, double-blind, placebo-controlled, cross-over trial on the effect of levetiracetam 3000 mg daily on pain in multiple sclerosis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
ms diagnosis verified
age > 18 years
central pain symptoms for more than 3 months
central pain diagnosis confirmed by neurological examination
adequate anticonceptive treatment for women with child bearing potential
baseline pain of more than 4 on numeric rating scale
other cause of pain
previous allergic reaction towards levetiracetam
known adverse drug reaction on levetiracetam
inability to follow study protocol
treatment with antidepressants, other anticonvulsants or opioids